Teyssedou Lenaic Nathanael disposed of 602,908 derivative securities and was awarded 602,908 derivative securities in Addex Therapeutics Ltd. transactions dated 2026-09-02, each at $0 per share. For investors, the key distinction is that the two transaction sets carry different reported post-transaction ownership totals.
Key Highlights
- The transactions were dated 2 September 2026 and carried a stated price of $0 per share.
- Teyssedou Lenaic Nathanael is identified as Addex Therapeutics Ltd.’s principal accounting officer.
- Reported post-transaction holdings were 502,423 derivative securities after the disposals and 602,908 after the awards.
Teyssedou Lenaic Nathanael completed two sets of derivative-security transactions involving Addex Therapeutics Ltd. with each set covering 602,908 securities. The records show both disposals and awards, creating separate post-transaction ownership figures for the principal accounting officer.
Addex Derivative-Security Transactions Recorded
The transactions took place on 2 September 2026, with each priced at $0 per share. Teyssedou Lenaic Nathanael disposed of 602,908 derivative securities through 8 separate transactions. Those awards carried transaction code A. Teyssedou Lenaic Nathanael is identified as Addex Therapeutics Ltd.’s principal accounting officer.
Following the disposals, Teyssedou Lenaic Nathanael’s reported ownership stood at 502,423 derivative securities. Following the awards, the reported ownership was 602,908 derivative securities. The ownership totals are tied to separate transaction sets.
FAQs
Q: What Addex derivative securities transactions did Teyssedou Lenaic Nathanael record?
A: Teyssedou Lenaic Nathanael disposed of 602,908 derivative securities and was awarded 602,908 derivative securities. Both transaction sets were dated 2 September 2026 and priced at $0 per share.
Q: What was Teyssedou Lenaic Nathanael’s reported ownership after the transactions?
A: Following the disposals, the filing reported that Teyssedou Lenaic Nathanael owned 502,423 derivative securities. Following the awards, it reported ownership of 602,908 derivative securities.
Q: What role does Teyssedou Lenaic Nathanael hold at Addex Therapeutics?
A: Teyssedou Lenaic Nathanael is identified as Addex Therapeutics Ltd.’s principal accounting officer. The transactions involved derivative securities of Addex Therapeutics Ltd.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.